share_log

东诚药业(002675.SZ):子公司蓝纳成获得药物临床试验批准通知书

Yantai Dongcheng Biochemicals (002675.SZ): Its subsidiary, Lanna Cheng, has obtained the approval notice for drug clinical trials.

Gelonghui Finance ·  Aug 2, 2024 05:44

On August 2, 2024, Yantai Blue Nano Biology Technology Co., Ltd, a subsidiary of Yantai Dongcheng Biochemicals (002675.SZ), received the drug clinical trial approval notice of 177Lu-LNC1011 injection from China National Medical Products Administration (NMPA) and will conduct clinical trials soon.

The company's in-development product, 177Lu-LNC1011 injection, is a targeted radiopharmaceutical drug for the treatment of PSMA-positive advanced prostate cancer patients. According to public data, there is currently only one drug on the global market targeting the same point, Pluvicto, by Novartis. Pluvicto sales in 2023 reached 0.98 billion USD, and in H1 2024 sales reached 0.655 billion USD.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment